• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

肿瘤内异质性分析揭示肺癌的演变。

Analysis of intratumor heterogeneity unravels lung cancer evolution.

作者信息

de Bruin Elza C, McGranahan Nicholas, Swanton Charles

机构信息

Cancer Institute; UK by Cancer Institute ; London, UK.

Centre for Mathematics & Physics in the Life Science & Experimental Biology (CoMPLEX); University College London; London, UK; Cancer Research UK London Research Institute; London, UK.

出版信息

Mol Cell Oncol. 2015 Apr 1;2(3):e985549. doi: 10.4161/23723556.2014.985549. eCollection 2015 Jul-Sep.

DOI:10.4161/23723556.2014.985549
PMID:27308463
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4905299/
Abstract

Lung cancer is a disease with dismal outcome. We recently reported a detailed intratumor heterogeneity analysis in 7 non-small cell lung cancer samples, revealing spatially separated driver events as well as the temporal dynamics of mutational processes and demonstrating an important role for APOBEC-mediated heterogeneity later in disease evolution.

摘要

肺癌是一种预后不佳的疾病。我们最近报告了对7个非小细胞肺癌样本进行的详细肿瘤内异质性分析，揭示了空间上分离的驱动事件以及突变过程的时间动态，并证明了APOBEC介导的异质性在疾病后期演变中的重要作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7f74/4905299/71569c6f011d/kmco-02-03-985549-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7f74/4905299/71569c6f011d/kmco-02-03-985549-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7f74/4905299/71569c6f011d/kmco-02-03-985549-g001.jpg

相似文献

1
Analysis of intratumor heterogeneity unravels lung cancer evolution.肿瘤内异质性分析揭示肺癌的演变。
Mol Cell Oncol. 2015 Apr 1;2(3):e985549. doi: 10.4161/23723556.2014.985549. eCollection 2015 Jul-Sep.
2
Tracking the Evolution of Non-Small-Cell Lung Cancer.跟踪非小细胞肺癌的演变。
N Engl J Med. 2017 Jun 1;376(22):2109-2121. doi: 10.1056/NEJMoa1616288. Epub 2017 Apr 26.
3
APOBEC Mutagenesis and Copy-Number Alterations Are Drivers of Proteogenomic Tumor Evolution and Heterogeneity in Metastatic Thoracic Tumors.APOBEC 诱变和拷贝数改变是转移性胸肿瘤的蛋白质基因组肿瘤进化和异质性的驱动因素。
Cell Rep. 2019 Mar 5;26(10):2651-2666.e6. doi: 10.1016/j.celrep.2019.02.028.
4
APOBEC Enzymes: Mutagenic Fuel for Cancer Evolution and Heterogeneity.载脂蛋白B编辑酶：癌症演变与异质性的致突变驱动力
Cancer Discov. 2015 Jul;5(7):704-12. doi: 10.1158/2159-8290.CD-15-0344. Epub 2015 Jun 19.
5
APOBEC3 as a driver of genetic intratumor heterogeneity.载脂蛋白B mRNA编辑酶催化多肽样蛋白3作为肿瘤内基因异质性的驱动因素。
Mol Cell Oncol. 2022 Jan 3;10(1):2014734. doi: 10.1080/23723556.2021.2014734. eCollection 2023.
6
Spatial and temporal diversity in genomic instability processes defines lung cancer evolution.基因组不稳定性过程中的空间和时间多样性定义了肺癌的进化。
Science. 2014 Oct 10;346(6206):251-6. doi: 10.1126/science.1253462.
7
Intratumor heterogeneity and branched evolution revealed by multiregion sequencing.多区域测序揭示的肿瘤内异质性和分支进化。
N Engl J Med. 2012 Mar 8;366(10):883-892. doi: 10.1056/NEJMoa1113205.
8
APOBEC3 Activity Promotes the Survival and Evolution of Drug-Tolerant Persister Cells during EGFR Inhibitor Resistance in Lung Cancer.载脂蛋白B编辑酶催化多肽样蛋白3（APOBEC3）的活性促进肺癌表皮生长因子受体（EGFR）抑制剂耐药期间药物耐受持久性细胞的存活和进化。
Cancer Res Commun. 2025 May 1;5(5):825-840. doi: 10.1158/2767-9764.CRC-24-0442.
9
Multi-region sequencing depicts intratumor heterogeneity and clonal evolution in cervical cancer.多区域测序描绘了宫颈癌中的肿瘤内异质性和克隆进化。
Med Oncol. 2023 Jan 12;40(2):78. doi: 10.1007/s12032-022-01942-2.
10
Multiregion sequencing reveals the intratumor heterogeneity of driver mutations in TP53-driven non-small cell lung cancer.多区域测序揭示了TP53驱动的非小细胞肺癌中驱动基因突变的肿瘤内异质性。
Int J Cancer. 2017 Jan 1;140(1):103-108. doi: 10.1002/ijc.30437. Epub 2016 Oct 3.

引用本文的文献

1
The role of APOBEC3B in lung tumor evolution and targeted cancer therapy resistance.APOBEC3B 在肺肿瘤进化和靶向癌症治疗耐药中的作用。
Nat Genet. 2024 Jan;56(1):60-73. doi: 10.1038/s41588-023-01592-8. Epub 2023 Dec 4.
2
Development of EGFR TKIs and Options to Manage Resistance of Third-Generation EGFR TKI Osimertinib: Conventional Ways and Immune Checkpoint Inhibitors.表皮生长因子受体酪氨酸激酶抑制剂的发展以及应对第三代表皮生长因子受体酪氨酸激酶抑制剂奥希替尼耐药的策略：传统方法与免疫检查点抑制剂
Front Oncol. 2020 Dec 18;10:602762. doi: 10.3389/fonc.2020.602762. eCollection 2020.
3
New additional scoring formula on the Pathological Features in Stage I Lung Adenocarcinoma Patients: Impact on Survival.

本文引用的文献

1
Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing.多区域测序描绘的局限性肺腺癌肿瘤内异质性。
Science. 2014 Oct 10;346(6206):256-9. doi: 10.1126/science.1256930.
2
Spatial and temporal diversity in genomic instability processes defines lung cancer evolution.基因组不稳定性过程中的空间和时间多样性定义了肺癌的进化。
Science. 2014 Oct 10;346(6206):251-6. doi: 10.1126/science.1253462.
3
Tracking genomic cancer evolution for precision medicine: the lung TRACERx study.追踪基因组癌症演变以实现精准医疗：肺癌TRACERx研究。
I期肺腺癌患者病理特征的新附加评分公式：对生存的影响
Int J Med Sci. 2020 Jul 19;17(13):1871-1878. doi: 10.7150/ijms.45002. eCollection 2020.
4
[Acquired Drug Resistance Mechanism of Osimertinib in the Targeted Therapy of Non-small Cell Lung Cancer].[奥希替尼在非小细胞肺癌靶向治疗中的获得性耐药机制]
Zhongguo Fei Ai Za Zhi. 2020 Apr 20;23(4):274-281. doi: 10.3779/j.issn.1009-3419.2020.103.02.
5
Comparative expression analysis in small cell lung carcinoma reveals neuroendocrine pattern change in primary tumor versus lymph node metastases.小细胞肺癌中的比较表达分析揭示了原发性肿瘤与淋巴结转移灶之间神经内分泌模式的变化。
Transl Lung Cancer Res. 2019 Dec;8(6):938-950. doi: 10.21037/tlcr.2019.11.30.
6
Cancer biology as revealed by the research autopsy.研究尸检揭示的癌症生物学
Nat Rev Cancer. 2019 Dec;19(12):686-697. doi: 10.1038/s41568-019-0199-4. Epub 2019 Sep 13.
7
Monitoring Therapeutic Response and Resistance: Analysis of Circulating Tumor DNA in Patients With ALK+ Lung Cancer.监测治疗反应和耐药性：ALK+肺癌患者循环肿瘤 DNA 分析。
J Thorac Oncol. 2019 Nov;14(11):1901-1911. doi: 10.1016/j.jtho.2019.08.003. Epub 2019 Aug 22.
8
Somatic Mutations in miRNA Genes in Lung Cancer-Potential Functional Consequences of Non-Coding Sequence Variants.肺癌中miRNA基因的体细胞突变——非编码序列变异的潜在功能后果
Cancers (Basel). 2019 Jun 8;11(6):793. doi: 10.3390/cancers11060793.
9
Plasma genotyping in patients with non-small-cell lung cancer: simplifying or confusing the diagnosis?非小细胞肺癌患者的血浆基因分型：是简化还是混淆诊断？
Lung Cancer Manag. 2017 Jul;6(1):29-37. doi: 10.2217/lmt-2016-0019. Epub 2017 May 19.
10
Intratumor and Intertumor Heterogeneity in Melanoma.黑色素瘤的肿瘤内和肿瘤间异质性
Transl Oncol. 2017 Dec;10(6):956-975. doi: 10.1016/j.tranon.2017.09.007. Epub 2017 Oct 24.
PLoS Biol. 2014 Jul 8;12(7):e1001906. doi: 10.1371/journal.pbio.1001906. eCollection 2014 Jul.
4
Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing.多区域测序定义的透明细胞肾细胞癌的基因组结构和演化。
Nat Genet. 2014 Mar;46(3):225-233. doi: 10.1038/ng.2891. Epub 2014 Feb 2.
5
Signatures of mutational processes in human cancer.人类癌症中的突变过程特征。
Nature. 2013 Aug 22;500(7463):415-21. doi: 10.1038/nature12477. Epub 2013 Aug 14.
6
An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers.APOBEC 胞嘧啶脱氨酶致突变模式广泛存在于人类癌症中。
Nat Genet. 2013 Sep;45(9):970-6. doi: 10.1038/ng.2702. Epub 2013 Jul 14.
7
Evidence for APOBEC3B mutagenesis in multiple human cancers.APOBEC3B 突变在多种人类癌症中的证据。
Nat Genet. 2013 Sep;45(9):977-83. doi: 10.1038/ng.2701. Epub 2013 Jul 14.
8
Genomic landscape of non-small cell lung cancer in smokers and never-smokers.吸烟者和不吸烟者非小细胞肺癌的基因组图谱。
Cell. 2012 Sep 14;150(6):1121-34. doi: 10.1016/j.cell.2012.08.024.
9
Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing.大规模平行测序绘制肺腺癌特征图谱。
Cell. 2012 Sep 14;150(6):1107-20. doi: 10.1016/j.cell.2012.08.029.
10
Somatic mutations affect key pathways in lung adenocarcinoma.体细胞突变影响肺腺癌的关键通路。
Nature. 2008 Oct 23;455(7216):1069-75. doi: 10.1038/nature07423.